Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Dipeptidyl Peptidase-4 Inhibitors and COVID-19-Related Deaths among Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Observational Studies
Authors
Keywords
-
Journal
Endocrinology and Metabolism
Volume 36, Issue 4, Pages 904-908
Publisher
Korean Endocrine Society
Online
2021-07-27
DOI
10.3803/enm.2021.1048
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Association Between DPP-4 Inhibitors and COVID-19 Related Outcomes Among Patients With Type 2 Diabetes
- (2021) Yunha Noh et al. DIABETES CARE
- Comparable COVID ‐19 outcomes with current use of GLP ‐1 receptor agonists, DPP ‐4 inhibitors or SGLT ‐2 inhibitors among patients with diabetes who tested positive for SARS‐CoV ‐2
- (2021) Simone Bastrup Israelsen et al. DIABETES OBESITY & METABOLISM
- Predictors of hospital discharge and mortality in patients with diabetes and COVID-19: updated results from the nationwide CORONADO study
- (2021) Matthieu Wargny et al. DIABETOLOGIA
- Disentangling conflicting evidence on DPP-4 inhibitors and outcomes of COVID-19: narrative review and meta-analysis
- (2021) B. M. Bonora et al. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION
- Clinical Characteristics and Outcomes of Patients With Diabetes and COVID-19 in Association With Glucose-Lowering Medication
- (2020) Yuchen Chen et al. DIABETES CARE
- Exposure to DPP ‐4 inhibitors and COVID ‐19 among people with type 2 diabetes. A case–control study
- (2020) Gian Paolo Fadini et al. DIABETES OBESITY & METABOLISM
- COVID-19 and diabetes: Can DPP4 inhibition play a role?
- (2020) Gianluca Iacobellis DIABETES RESEARCH AND CLINICAL PRACTICE
- Sitagliptin Treatment at the Time of Hospitalization Was Associated With Reduced Mortality in Patients With Type 2 Diabetes and COVID-19: A Multicenter, Case-Control, Retrospective, Observational Study
- (2020) Sebastiano Bruno Solerte et al. DIABETES CARE
- Impact of Comorbidities and Glycemia at Admission and Dipeptidyl Peptidase 4 Inhibitors in Patients With Type 2 Diabetes With COVID-19: A Case Series From an Academic Hospital in Lombardy, Italy
- (2020) Marco Mirani et al. DIABETES CARE
- Are diabetes and its medications risk factors for the development of COVID-19? Data from a population-based study in Sicily
- (2020) Silverii Giovanni Antonio et al. NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES
- Diabetes and COVID-19: A pooled analysis related to disease severity and mortality
- (2020) Seshadri Reddy Varikasuvu et al. Primary Care Diabetes
- Mortality and other adverse outcomes in patients with type 2 diabetes mellitus admitted for COVID-19 in association with glucose-lowering drugs: a nationwide cohort study
- (2020) Luis M. Pérez-Belmonte et al. BMC Medicine
- A meta-analysis on the preadmission use of DPP-4 inhibitors and risk of a fatal or severe course of illness in patients with COVID-19
- (2020) Chia Siang Kow et al. THERAPIE
- No significant association between dipeptidyl peptidase-4 inhibitors and adverse outcomes of COVID-19
- (2020) Jiang-Hua Zhou et al. World Journal of Clinical Cases
- DPP-4 inhibition and COVID-19: From initial concerns to recent expectations
- (2020) André J. Scheen DIABETES & METABOLISM
- DPP4 inhibition by sitagliptin attenuates LPS-induced lung injury in mice
- (2018) Takeshi Kawasaki et al. AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now